Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: Genetic prostate cancer risk

AACR 2009

18 - 22 Apr 2009

Published: 30 Apr 2009

Views: 15702

Rating:

Save

Dr Sunita Setlur - Brigham and Women's Hospital, Harvard Medical School, USA

Sunita Setlur, Ph.D., post doctoral fellow, Brigham and Women’s Hospital, Harvard Medical School, presents at AACR 2009, Denver: Association of UGT2B17, UGT2B7 and UGT2B28 Gene Copy Number with Prostate Cancer Risk

Related Videos

ESMO 2024: Latest updates in mRCC

Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane...

ESMO 2024: Latest updates in mRCC ( Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane Oudard )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof...

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel...

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

ARV-766 well tolerated and shows promising clinical activity in metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

ASCO 2024: Latest in mRCC treatment

Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas...

ASCO 2024: Latest in mRCC treatment ( Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas Powles )

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive...

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer ( Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy )

More from ecancer